NANPING, China, June 19, 2020 /PRNewswire/ -- Happiness Biotech
Group Limited (the "Company" or Nasdaq: HAPP), an innovative
China-based nutraceutical and
dietary supplements producer, announced today that the Company has
obtained the CE Certification for the Company's COVID-19 anti-body
testing kits on June 5, 2020 and
samples of these testing kits have been shipped to countries
including Uganda, Malaysia, and Canada since last week.
CFDA has changed the approval policy for new testing kits for
COVID-19 on March 30, 2020 and
required more information for new applications. As a result, our
CFDA application has been delayed. On April
25, 2020, Ministry of Commerce issued Announcement on
Further Strengthening the Quality Supervision of Export Epidemic
Prevention Materials stating that COVID-19 testing kits may be sold
to overseas market without CFDA approval so long as the testing
kits receives the importing country's appropriate approval. On
June 5, the Company successfully
obtained the CE certification for
COVID-19 anti-body testing kits. CE
certification is a mandatory requirement for products to market in
Europe. In the meantime,
the Company has been reaching out to potential clients in different
countries including Uganda,
Malaysia and Canada. On June
10, the Company participated in the Guangzhou International
Anti-Epidemic Products Exhibition, displaying our COVID-19
anti-body testing kits.
"We know our investors are keen to receive updated information
about our COVID-19 anti-body testing kits and we are proud to
announce today what we have accomplished in the past two months.
The first batch of 10,000 COVID-19 anti-body testing kits is ready
for shipment to any clients in the European countries and we will
continue to apply for the required approvals in more countries and
areas. We hope the orders will start to come soon," said Mr.
Xuezhu Wang, CEO of the Company.
About Happiness Biotech Group Limited
Headquartered in Nanping, China, Happiness Biotech Group Limited is an
innovative China-based
nutraceutical and dietary supplements producer focused on the
research, development, manufacturing and marketing of a variety of
products made from Chinese herbal extracts and other ingredients.
The Company's goal is to provide high-quality products to our
consumers. Over the past 14 years, the Company has established a
product portfolio consisting of 32 CFDA registered "Blue-Cap" SKUs
of nutraceutical and dietary supplements products. For more
information, please visit: www.happ.org.cn.
Forward-Looking Statements
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; economic conditions; reputation
and brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China; the COVID-19
outbreak and its impact on our operations and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the Securities and
Exchange Commission. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the U.S. Securities and Exchange
Commission, which are available for review at www.sec.gov. The
Company undertakes no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date hereof.
View original
content:http://www.prnewswire.com/news-releases/happiness-biotech-announced-progress-of-covid-19-testing-kits-301079671.html
SOURCE Happiness Biotech Group Limited